ENDP vs. CALA, SCPS, ATHX, APVO, AMPE, OBSV, ALLR, SXTC, ADTX, and PTEIQ
Should you be buying Endo International stock or one of its competitors? The main competitors of Endo International include Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Athersys (ATHX), Aptevo Therapeutics (APVO), Ampio Pharmaceuticals (AMPE), ObsEva (OBSV), Allarity Therapeutics (ALLR), China SXT Pharmaceuticals (SXTC), Aditxt (ADTX), and PolarityTE (PTEIQ). These companies are all part of the "medical" sector.
Calithera Biosciences (NASDAQ:CALA) and Endo International (NASDAQ:ENDP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.
Calithera Biosciences has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, Endo International has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
In the previous week, Calithera Biosciences had 1 more articles in the media than Endo International. MarketBeat recorded 2 mentions for Calithera Biosciences and 1 mentions for Endo International. Calithera Biosciences' average media sentiment score of 0.01 beat Endo International's score of 0.00 indicating that Endo International is being referred to more favorably in the news media.
Endo International received 580 more outperform votes than Calithera Biosciences when rated by MarketBeat users. Likewise, 63.74% of users gave Endo International an outperform vote while only 59.82% of users gave Calithera Biosciences an outperform vote.
80.4% of Endo International shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 1.2% of Endo International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Calithera Biosciences has a net margin of 0.00% compared to Calithera Biosciences' net margin of -93.31%. Endo International's return on equity of 0.00% beat Calithera Biosciences' return on equity.
Calithera Biosciences has higher earnings, but lower revenue than Endo International.
Summary
Endo International beats Calithera Biosciences on 7 of the 13 factors compared between the two stocks.
Get Endo International News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Endo International Competitors List
Related Companies and Tools
